Presentation of Assessa® PML at ECTRIMS

RNS Number : 6232J

IXICO plc

13 September 2016

 

IXICO presents Assessa® PML digital healthcare platform supported by Biogen

 at International Multiple Sclerosis Congress

13 September 2016, IXICO plc (AIM: IXI) ('IXICO' or the 'Company'), the brain health company, is presenting its Assessa® PML digital healthcare platform at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress on 16 September 2016. Assessa® PML  is based on IXICO's existing Assessa® technology, and has been designed as part of a collaboration including IXICO, clinical experts in specialist centres in The Netherlands, Germany, Switzerland, France, Italy, Spain and UK, with financial support from Biogen Inc., (NASDAQ: BIIB) through a collaboration agreement announced in October 2015.   

Progressive Multifocal Leukoencephalopathy (PML) is a potentially fatal side effect of certain drug treatments for Multiple Sclerosis (MS). Assessa® PML is designed to be used alongside such drugs to support the early detection of PML.  It could therefore improve uptake of effective treatments by providing improved management of PML risks.

The authors of the ECTRIMS presentation describe a consensus position on the use of the Assessa® PML digital platform in a clinical setting following a confidential structured workshop in May 2016.

Assessa® PML, currently in beta testing with referring clinicians and expert neuroradiologists in European Centres, supports clinical decision making by providing access to second opinion reading expertise of MRI scans from MS patients with PML suspicion.  It facilitates the secure transfer and storage of patient data and second opinion reports between treating physicians and expert neuroradiologists.  Feedback will be used to enhance the usability and functionality of Assessa® PML prior to production roll-out.  

Derek Hill, CEO of IXICO, said:

"We are delighted to be leading this initiative with our pharmaceutical and clinical collaborators. The development of Assessa® PML represents clear progress in expanding our digital technologies across a broad range of brain diseases. This demonstrates the value of using our Assessa® platform in a clinical setting, enabling physicians to assess and implement the best therapeutic treatments for patients with Multiple Sclerosis."

IXICO Exhibition stand:
Stand Number:	E22
Dates:	14-17 September 2016
Poster Presentation:
Title:	Creating a consensus evaluation and expert opinion reporting platform for brain MRI in Multiple Sclerosis with higher increased risk of Progressive Multifocal Leukoencephalopathy
Authorship:	F. Barkhof, S. Llufriu, À. Rovira, A. Gass, C. Gasperini, H. Kitzler, J. Hodel, J. Chataway, T. Ziemssen, M. Wattjes, J. Killestein, P. Vermersch, J. Hall, S. Grootoonk, N. Royle, D. Hill, T. Yousry
Session Title:	Poster Session 2
Session Date:	Friday, 16 September 2016
Session Time:	15:30-17:00

Enquiries:

IXICO plc	[phone]
Derek Hill, CEO
Susan Lowther, CFO
Peel Hunt LLP (Nominated Adviser)	[phone]
James Steel / Oliver Jackson
FTI Consulting Limited (Investor Relations)	[phone]
Simon Conway / Mo Noonan / Matthew Moss

Notes to Editors

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions.  In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes.  In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

About Progressive Multifocal Leukoencephalopathy (PML)

Progressive Multifocal Leukoencephalopathy (PML) is a severe side effect of several MS immunotherapeutics and a challenge for modern treatment strategies.  MRI is very sensitive to PML and can detect asymptomatic PML.  However lesion differentiation is challenging and requires dedicated neuroradiology expertise, which is scarce outside specialised centres.  

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world's oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.

More information is available on www.biogen.com.

 

END

 

 

MSCGGUAUBUPQGBP